Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn about a recent article by Danny Luan et al, published in Blood:
“Circadian rhythm strikes again!
Recent (albeit retrospective) analysis suggests that ‘patients receiving CAR-T therapy in the morning experienced improved outcomes compared with those treated later in the day’.
If correct, changing the way we deliver cancer therapy may improve outcomes. Proud that we are funding this area of research at Parker Institute for Cancer Immunotherapy.
Look for more…”
Title: Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma
Authors: Danny Luan, Ori Ben Valid, Ofrat Beyar-Katz, Tobias Tix, Noa Golan-Accav, Mohammad Alhomoud, Abraham Avigdor, Veit L. Bücklein, Limor Cohen, Parastoo B Dahi, Sigrun Einarsdottir, Julia Elimelech, Silvia Escribano Serrat, Lorenzo Falchi, Teng Fei, Sergio A. Giralt, Marina Gomez-Llobell, Andre Goy, Nurit Horesh, Sapir Israeli, Linus Kruk, Lori A. Leslie, Jennifer K Lue, Ronit Marcus, Arnon Nagler, M. Lia Palomba, Jae H Park, Sandeep S Raj, Siddhartha Thammineni Reddy, Jason T. Romancik, Efrat Rosenbaum, Gilles A. Salles, Michael Scordo, Gunjan L. Shah, Avichai Shimoni, Michael von Bergwelt-Baildon, Miguel-Angel Perales, Marion Subklewe, Uri Greenbaum, Andrew Ip, Ron Ram, Kai Rejeski, Roni Shouval
Read the Full Article on Blood
More posts featuring Karen Knudsen.